Share

    


Home / Search Results

Search Results

You searched for:

ACCCBuzz spoke with Dr. Jessica Unzaga at Baptist Health’s Miami Cancer Institute, to help consider the use of triplet vs. quadruplet regimens in the treatment of multiple myeloma.
ACCCBuzz spoke with Dr. Dan Vogl to learn more about the treatment options available to patients with multiple myeloma, including the benefits of adding anti-CD38 monoclonal antibodies in either first- or second-line treatment.
Measurable residual disease (MRD) has gained traction as a compelling marker for disease status across various hematologic malignancies, including multiple myeloma. Learn how MRD is uniquely suited to help evaluate the depth of treatment response.
Testing for measurable residual disease can shape treatment choices and patient management to achieve better outcomes, and the need persists for members of the multidisciplinary cancer care team to better understand the purpose, use, and significance of this testing in all cancer treatment settings.
March is Multiple Myeloma Awareness Month. Learn how ACCC is supporting collaboration among healthcare providers with practical, scalable solutions to the real-world challenges of improving quality care delivery for patients with multiple myeloma.